Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages

Pulmonary Deposition and Elimination of Liposomal Amikacin for Inhalation and Effect on Macrophage Function after Administration in Rats

(2016) Vladimir Malinin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Molecular basis of mycobacterial survival in macrophages

(2016) Jane Atesoh Awuh et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

The antimicrobial susceptibility of non-tuberculous mycobacteria

(2016) S. Cowman et al.   JOURNAL OF INFECTION

Chronic pulmonary disease withMycobacterium abscessuscomplex is a biofilm infection

(2015) Tavs Qvist et al.   EUROPEAN RESPIRATORY JOURNAL

Drug susceptibility testing of nontuberculous mycobacteria

(2014) Jakko van Ingen et al.   Future Microbiology

Delivery of Aerosolized Liposomal Amikacin as a Novel Approach for the Treatment of Nontuberculous Mycobacteria in an Experimental Model of Pulmonary Infection

(2014) Sasha J. Rose et al.   PLoS One

In Vitro Activity of Amikacin against Isolates of Mycobacterium avium Complex with Proposed MIC Breakpoints and Finding of a 16S rRNA Gene Mutation in Treated Isolates

(2013) B. A. Brown-Elliott et al.   JOURNAL OF CLINICAL MICROBIOLOGY

A Gamma Scintigraphy Study to Investigate Lung Deposition and Clearance of Inhaled Amikacin-Loaded Liposomes in Healthy Male Volunteers

(2009) Jeffry Weers et al.   Journal of Aerosol Medicine and Pulmonary Drug Delivery

Characterization of Nebulized Liposomal Amikacin (Arikace™) as a Function of Droplet Size

(2008) Zhili Li et al.   Journal of Aerosol Medicine and Pulmonary Drug Delivery

Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections

(2008) P. Meers et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY